Please use this identifier to cite or link to this item:
|Title:||Antibodies in oncology.|
|Authors:||Pillay, Vinochani;Gan, Hui K;Scott, Andrew M|
|Affiliation:||Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria 3084, Australia.|
|Citation:||New Biotechnology 2011; 28(5): 518-29|
|Abstract:||Monoclonal antibodies (mAbs) have become one of the largest classes of new therapeutic agents approved for use in oncology, and have revolutionised the treatment of many human malignancies. Clinically useful mAbs can function through several different mechanisms, including inhibition of tumour-related signalling, induction of apoptosis, inhibition of angiogenesis, enhancing host immune response against cancer and targeted delivery of payloads (such as toxins, cytotoxic agents or radioisotopes) to the tumour site. The increasing knowledge of key molecules and cellular pathways involved in tumour induction and progression has led to a rise in the proportion of therapeutic mAbs entering clinical trials. These mAbs consist of various conventional or recombinant, murine, humanised, chimeric or fully human and fusion constructs. In this review, we provide an overview of mAbs approved for use in clinical oncology and those currently in clinical development. We also discuss the mechanisms of action of anti-cancer mAbs, as well as the antigen targets recognised by these antibodies.|
|Internal ID Number:||21473941|
Antibodies, Monoclonal.immunology.therapeutic use
Antineoplastic Agents.immunology.therapeutic use
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.